Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers November 20, 2017
Pharmacy Choice - Pharmaceutical News - Audentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT342 to Treat Crigler-Najjar Syndrome - November 20, 2017

Pharmacy News Article

 2/15/17 - Audentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT342 to Treat Crigler-Najjar Syndrome

By a News Reporter-Staff News Editor at Biotech Week - Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for AT342, the Company's gene therapy product candidate to treat Crigler-Najjar Syndrome. The IND is now active and Audentes plans to initiate VALENS, the multicenter, multinational, open-label, ascending dose phase 1/2 clinical study of AT342. Preliminary data from VALENS is expected to be available by the end of 2017 (see also Audentes Therapeutics, Inc.).

"We are pleased to achieve this important milestone and look forward to working with regulatory authorities and the medical and patient communities to evaluate AT342 for the treatment of this serious, life-threatening disease," stated Matthew R. Patterson, President and Chief Executive Officer of Audentes Therapeutics. "Based on our thorough preclinical investigation, we believe that AT342 has the potential to provide a significant and durable reduction in serum bilirubin levels, to reduce or eliminate the need for daily phototherapy treatment, to decrease the risk of devastating neurological injury, and to significantly improve the quality of life for Crigler-Najjar patients and their families."

In addition to VALENS, Audentes plans to imminently begin LUSTRO, a clinical assessment and run-in study. LUSTRO is designed to enroll 16 to 18 Crigler-Najjar patients greater than one year of age and to characterize their disease course, natural history, bilirubin variability and phototherapy usage. The study is intended to identify patients for potential enrollment in VALENS and to serve as a within-patient control for VALENS.

AT342 has been developed in collaboration with the University of Pennsylvania (Penn) under the leadership of James M. Wilson, M.D., Ph.D., a pioneer in human gene therapy and the director of the Gene Therapy Program and the Orphan Disease Center at the Perelman School of Medicine. As part of the collaboration, Penn has licensed certain Penn-owned AAV technologies to Audentes, including rights related to AT342.

Editor's Note: Dr. Wilson reports no direct financial conflict of interest related to Audentes.

Keywords for this news article include: Biotechnology, Pharmaceuticals, Genetics, Gene Therapy, Phototherapy, Photomedicine, Bioengineering, Drugs and Therapies, Crigler-Najjar Syndrome, Audentes Therapeutics Inc., Hereditary Hyperbilirubinemia, Government Agencies Offices and Entities, Nutritional and Metabolic Diseases and Conditions.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Nov 20: Obesity Management: Overview of Pharmacotherapy
Last Chance
Nov 21: Standards of Practice for Filling Controlled Substance Prescriptions in Florida
Last Chance
Nov 22: Medical Marijuana: Examining the Science, Not the Politics
Nov 27: Drug Diversion and the Law: Updates and Considerations
Nov 28: An Integrative Approach to Managing Arthritis
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement